
Integrin αvβ3-targeted radionuclide therapy combined with …
Oct 16, 2019 · The peptide containing Arg-Gly-Asp (RGD) sequence specifically targets the cell surface receptor integrin α v ß 3, which is overexpressed in various malignancies 24. As such, …
Integrin-targeted cancer immunotherapy elicits protective …
Jun 6, 2017 · An anti–PD-1 antibody combined with MSA/IL-2 and 2.5F-Fc results in significantly improved antitumor efficacy relative to single or double treatments in MC38 colon carcinoma …
Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles …
Dec 4, 2020 · MC38 tumor-bearing mice were administered with RGD-LNP encapsulating either si PLK1 as a control, or si Vegfr2, at a dose of 40 μg siRNA. Tumors were harvested 24 h after …
Synergism of 64Cu-Labeled RGD with Anti-PD-L1 Immunotherapy …
Nov 16, 2022 · In the MC38 tumor model, anti-PD-L1 antibody (αPD-L1 mAb) was delivered in a concurrent or sequential manner after 64 Cu-DER was injected, followed by the testing of …
Developments in Combining Targeted Radionuclide Therapies and ...
Using a different radionuclide and vector, Chen et al. demonstrated that 177 Lu bound to the α v β 3 integrin-targeting peptide Arg-Gly-Asp (177 Lu-RGD) improved tumor control and increased …
g Arg-Gly-Asp (RGD) sequence specifically targets the cell surface receptor integrin αvß3, which is overexpressed in va ious malignancies [24]. As such, RGD was identified as a promising …
Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts ...
Jun 18, 2024 · In the MC38-hPD-L1 murine colon cancer tumor model, under equivalent dosage conditions, CS1003 and nivolumab demonstrate comparable antitumor effects.
RGD Peptide Cell-Surface Display Enhances the Targeting and …
In this study, we used a novel, easy and straightforward approach to generate engineered Salmonella ΔppGpp strains displaying the arginine-glycine-aspartate (RGD) peptide on the …
Vascular normalization in MC38 tumors by knockdown of Vegfr2. MC38 …
MC38 tumor-bearing mice were administered with RGD-LNP encapsulating either siPLK1 as a control, or siVegfr2, at a dose of 40 μg siRNA twice, three days apart.
(A) Biodistribution of 177 Lu-EB-RGD in MC38 tumor bearing …
Haojun Chen et al. treated MC38 tumor-bearing C57BL/6 mice with 18.5 MBq 177 Lu-EB-RGD, which contained Arg-Gly-Asp (RGD) sequence specifically targets the cell surface receptor …